Casopitant improves the quality of life in patients receiving highly emetogenic chemotherapy
Purpose The control of chemotherapy-induced nausea and vomiting (CINV) is critical in preventing poor health outcomes and increasing patient quality of life. The objective of this study was to evaluate the impact of the addition of casopitant to dual-combination therapy of dexamethasone and ondanset...
Gespeichert in:
| Veröffentlicht in: | Supportive care in cancer 2010-11, Vol.18 (11), p.1437-1444 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1444 |
|---|---|
| container_issue | 11 |
| container_start_page | 1437 |
| container_title | Supportive care in cancer |
| container_volume | 18 |
| creator | Gridelli, Cesare Haiderali, Amin M. Russo, Mark W. Blackburn, Linda M. Lykopoulos, Konstantinos |
| description | Purpose
The control of chemotherapy-induced nausea and vomiting (CINV) is critical in preventing poor health outcomes and increasing patient quality of life. The objective of this study was to evaluate the impact of the addition of casopitant to dual-combination therapy of dexamethasone and ondansetron on quality of life in patients receiving highly emetogenic chemotherapy (HEC).
Methods
In a multicenter, double-blind, randomized, placebo-controlled, add-on trial (
N
= 810), patients were randomized to intravenous (IV) ondansetron/dexamethasone alone (control) or in combination with either a single 150-mg oral dose of casopitant or 3-day IV/oral casopitant. Quality of life was assessed as impact of nausea and vomiting on daily life using the Functional Living Index Emesis (FLIE) questionnaire. Patients completed the FLIE questionnaire at baseline prior to receiving chemotherapy and after completion of the first cycle of HEC.
Results
Patients in the single oral dose and 3-day IV/oral casopitant groups scored higher mean total FLIE scores (115.7 and 114.0, respectively;
p
≤ 0.0332) than patients in the control group (107.5), indicating that casopitant patients experienced less impact from nausea and vomiting on daily life. The overall absolute difference in the proportion of patients reporting CINV with no impact on daily life between the single oral casopitant group and the control group was 13%; the difference between the 3-day IV/oral casopitant group and the control group was 14%.
Conclusion
The addition of casopitant to ondansetron and dexamethasone in patients receiving HEC was significantly more effective in reducing the impact of nausea and vomiting on all daily life activities as assessed by the FLIE compared with ondansetron/dexamethasone dual therapy. |
| doi_str_mv | 10.1007/s00520-009-0766-4 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_journals_860959193</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A358058266</galeid><sourcerecordid>A358058266</sourcerecordid><originalsourceid>FETCH-LOGICAL-c437t-1cdbc67cb3fbfe57223519d105e320c25f6afb6e8208b3c59d0329638c5949a03</originalsourceid><addsrcrecordid>eNp1kV9rFTEQxYMo9rb6AXyRoM9bJ8kmu3ksl2qFgi_6JoRsdrI3Zf81yS3cb2_KXiiCMg8Zkt85M-EQ8oHBNQNoviQAyaEC0BU0SlX1K7JjtRBVI4R-TXaga1bVQsoLcpnSAwBrGsnfkgum25azRu3I771NyxqynTMN0xqXJ0w0H5A-Hu0Y8okuno7BIw0zXW0OOOdEIzoMT2Ee6CEMh_FEccK8DDgHR90Bp6UYRLue3pE33o4J35_PK_Lr6-3P_V11_-Pb9_3NfeVq0eSKub5zqnGd8J1H2XAuJNM9A4mCg-PSK-s7hS2HthNO6h4E10q0pa21BXFFPm2-Zf_HI6ZsHpZjnMtI0yrQUjMtCvR5gwY7ogmzX3K0bgrJmRshW5AtV6pQ1_-gSvU4BbfM6EO5_0vANoGLS0oRvVljmGw8GQbmOSWzpWRKSuY5JVMXzcfzvsduwv5FcY6lAHwDUnmaB4wvH_q_6x_y-5wm</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>860959193</pqid></control><display><type>article</type><title>Casopitant improves the quality of life in patients receiving highly emetogenic chemotherapy</title><source>MEDLINE</source><source>SpringerLink Journals</source><creator>Gridelli, Cesare ; Haiderali, Amin M. ; Russo, Mark W. ; Blackburn, Linda M. ; Lykopoulos, Konstantinos</creator><creatorcontrib>Gridelli, Cesare ; Haiderali, Amin M. ; Russo, Mark W. ; Blackburn, Linda M. ; Lykopoulos, Konstantinos</creatorcontrib><description>Purpose
The control of chemotherapy-induced nausea and vomiting (CINV) is critical in preventing poor health outcomes and increasing patient quality of life. The objective of this study was to evaluate the impact of the addition of casopitant to dual-combination therapy of dexamethasone and ondansetron on quality of life in patients receiving highly emetogenic chemotherapy (HEC).
Methods
In a multicenter, double-blind, randomized, placebo-controlled, add-on trial (
N
= 810), patients were randomized to intravenous (IV) ondansetron/dexamethasone alone (control) or in combination with either a single 150-mg oral dose of casopitant or 3-day IV/oral casopitant. Quality of life was assessed as impact of nausea and vomiting on daily life using the Functional Living Index Emesis (FLIE) questionnaire. Patients completed the FLIE questionnaire at baseline prior to receiving chemotherapy and after completion of the first cycle of HEC.
Results
Patients in the single oral dose and 3-day IV/oral casopitant groups scored higher mean total FLIE scores (115.7 and 114.0, respectively;
p
≤ 0.0332) than patients in the control group (107.5), indicating that casopitant patients experienced less impact from nausea and vomiting on daily life. The overall absolute difference in the proportion of patients reporting CINV with no impact on daily life between the single oral casopitant group and the control group was 13%; the difference between the 3-day IV/oral casopitant group and the control group was 14%.
Conclusion
The addition of casopitant to ondansetron and dexamethasone in patients receiving HEC was significantly more effective in reducing the impact of nausea and vomiting on all daily life activities as assessed by the FLIE compared with ondansetron/dexamethasone dual therapy.</description><identifier>ISSN: 0941-4355</identifier><identifier>EISSN: 1433-7339</identifier><identifier>DOI: 10.1007/s00520-009-0766-4</identifier><identifier>PMID: 19882176</identifier><language>eng</language><publisher>Berlin/Heidelberg: Springer-Verlag</publisher><subject><![CDATA[Activities of Daily Living ; Administration, Oral ; Adult ; Aged ; Aged, 80 and over ; Antiemetics - administration & dosage ; Antineoplastic Agents - adverse effects ; Antineoplastic Agents - therapeutic use ; Cancer ; Care and treatment ; Chemotherapy ; Clinical trials ; Dexamethasone ; Dexamethasone - therapeutic use ; Double-Blind Method ; Drug Therapy, Combination ; Female ; Health aspects ; Humans ; Male ; Medicine ; Medicine & Public Health ; Middle Aged ; Nausea ; Nausea - chemically induced ; Nausea - prevention & control ; Neoplasms - drug therapy ; Nursing ; Nursing Research ; Oncology ; Ondansetron - therapeutic use ; Original Article ; Pain Medicine ; Piperazines - administration & dosage ; Piperidines - administration & dosage ; Preventive medicine ; Quality of Life ; Rehabilitation Medicine ; Side effects ; Surveys and Questionnaires ; Vomiting ; Vomiting - chemically induced ; Vomiting - prevention & control ; Young Adult]]></subject><ispartof>Supportive care in cancer, 2010-11, Vol.18 (11), p.1437-1444</ispartof><rights>Springer-Verlag 2009</rights><rights>COPYRIGHT 2010 Springer</rights><rights>Springer-Verlag 2010</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c437t-1cdbc67cb3fbfe57223519d105e320c25f6afb6e8208b3c59d0329638c5949a03</citedby><cites>FETCH-LOGICAL-c437t-1cdbc67cb3fbfe57223519d105e320c25f6afb6e8208b3c59d0329638c5949a03</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s00520-009-0766-4$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s00520-009-0766-4$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,776,780,27901,27902,41464,42533,51294</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/19882176$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Gridelli, Cesare</creatorcontrib><creatorcontrib>Haiderali, Amin M.</creatorcontrib><creatorcontrib>Russo, Mark W.</creatorcontrib><creatorcontrib>Blackburn, Linda M.</creatorcontrib><creatorcontrib>Lykopoulos, Konstantinos</creatorcontrib><title>Casopitant improves the quality of life in patients receiving highly emetogenic chemotherapy</title><title>Supportive care in cancer</title><addtitle>Support Care Cancer</addtitle><addtitle>Support Care Cancer</addtitle><description>Purpose
The control of chemotherapy-induced nausea and vomiting (CINV) is critical in preventing poor health outcomes and increasing patient quality of life. The objective of this study was to evaluate the impact of the addition of casopitant to dual-combination therapy of dexamethasone and ondansetron on quality of life in patients receiving highly emetogenic chemotherapy (HEC).
Methods
In a multicenter, double-blind, randomized, placebo-controlled, add-on trial (
N
= 810), patients were randomized to intravenous (IV) ondansetron/dexamethasone alone (control) or in combination with either a single 150-mg oral dose of casopitant or 3-day IV/oral casopitant. Quality of life was assessed as impact of nausea and vomiting on daily life using the Functional Living Index Emesis (FLIE) questionnaire. Patients completed the FLIE questionnaire at baseline prior to receiving chemotherapy and after completion of the first cycle of HEC.
Results
Patients in the single oral dose and 3-day IV/oral casopitant groups scored higher mean total FLIE scores (115.7 and 114.0, respectively;
p
≤ 0.0332) than patients in the control group (107.5), indicating that casopitant patients experienced less impact from nausea and vomiting on daily life. The overall absolute difference in the proportion of patients reporting CINV with no impact on daily life between the single oral casopitant group and the control group was 13%; the difference between the 3-day IV/oral casopitant group and the control group was 14%.
Conclusion
The addition of casopitant to ondansetron and dexamethasone in patients receiving HEC was significantly more effective in reducing the impact of nausea and vomiting on all daily life activities as assessed by the FLIE compared with ondansetron/dexamethasone dual therapy.</description><subject>Activities of Daily Living</subject><subject>Administration, Oral</subject><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Antiemetics - administration & dosage</subject><subject>Antineoplastic Agents - adverse effects</subject><subject>Antineoplastic Agents - therapeutic use</subject><subject>Cancer</subject><subject>Care and treatment</subject><subject>Chemotherapy</subject><subject>Clinical trials</subject><subject>Dexamethasone</subject><subject>Dexamethasone - therapeutic use</subject><subject>Double-Blind Method</subject><subject>Drug Therapy, Combination</subject><subject>Female</subject><subject>Health aspects</subject><subject>Humans</subject><subject>Male</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Middle Aged</subject><subject>Nausea</subject><subject>Nausea - chemically induced</subject><subject>Nausea - prevention & control</subject><subject>Neoplasms - drug therapy</subject><subject>Nursing</subject><subject>Nursing Research</subject><subject>Oncology</subject><subject>Ondansetron - therapeutic use</subject><subject>Original Article</subject><subject>Pain Medicine</subject><subject>Piperazines - administration & dosage</subject><subject>Piperidines - administration & dosage</subject><subject>Preventive medicine</subject><subject>Quality of Life</subject><subject>Rehabilitation Medicine</subject><subject>Side effects</subject><subject>Surveys and Questionnaires</subject><subject>Vomiting</subject><subject>Vomiting - chemically induced</subject><subject>Vomiting - prevention & control</subject><subject>Young Adult</subject><issn>0941-4355</issn><issn>1433-7339</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2010</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNp1kV9rFTEQxYMo9rb6AXyRoM9bJ8kmu3ksl2qFgi_6JoRsdrI3Zf81yS3cb2_KXiiCMg8Zkt85M-EQ8oHBNQNoviQAyaEC0BU0SlX1K7JjtRBVI4R-TXaga1bVQsoLcpnSAwBrGsnfkgum25azRu3I771NyxqynTMN0xqXJ0w0H5A-Hu0Y8okuno7BIw0zXW0OOOdEIzoMT2Ee6CEMh_FEccK8DDgHR90Bp6UYRLue3pE33o4J35_PK_Lr6-3P_V11_-Pb9_3NfeVq0eSKub5zqnGd8J1H2XAuJNM9A4mCg-PSK-s7hS2HthNO6h4E10q0pa21BXFFPm2-Zf_HI6ZsHpZjnMtI0yrQUjMtCvR5gwY7ogmzX3K0bgrJmRshW5AtV6pQ1_-gSvU4BbfM6EO5_0vANoGLS0oRvVljmGw8GQbmOSWzpWRKSuY5JVMXzcfzvsduwv5FcY6lAHwDUnmaB4wvH_q_6x_y-5wm</recordid><startdate>20101101</startdate><enddate>20101101</enddate><creator>Gridelli, Cesare</creator><creator>Haiderali, Amin M.</creator><creator>Russo, Mark W.</creator><creator>Blackburn, Linda M.</creator><creator>Lykopoulos, Konstantinos</creator><general>Springer-Verlag</general><general>Springer</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>0-V</scope><scope>3V.</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>88J</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>ALSLI</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HEHIP</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>M2R</scope><scope>M2S</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope></search><sort><creationdate>20101101</creationdate><title>Casopitant improves the quality of life in patients receiving highly emetogenic chemotherapy</title><author>Gridelli, Cesare ; Haiderali, Amin M. ; Russo, Mark W. ; Blackburn, Linda M. ; Lykopoulos, Konstantinos</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c437t-1cdbc67cb3fbfe57223519d105e320c25f6afb6e8208b3c59d0329638c5949a03</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2010</creationdate><topic>Activities of Daily Living</topic><topic>Administration, Oral</topic><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Antiemetics - administration & dosage</topic><topic>Antineoplastic Agents - adverse effects</topic><topic>Antineoplastic Agents - therapeutic use</topic><topic>Cancer</topic><topic>Care and treatment</topic><topic>Chemotherapy</topic><topic>Clinical trials</topic><topic>Dexamethasone</topic><topic>Dexamethasone - therapeutic use</topic><topic>Double-Blind Method</topic><topic>Drug Therapy, Combination</topic><topic>Female</topic><topic>Health aspects</topic><topic>Humans</topic><topic>Male</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Middle Aged</topic><topic>Nausea</topic><topic>Nausea - chemically induced</topic><topic>Nausea - prevention & control</topic><topic>Neoplasms - drug therapy</topic><topic>Nursing</topic><topic>Nursing Research</topic><topic>Oncology</topic><topic>Ondansetron - therapeutic use</topic><topic>Original Article</topic><topic>Pain Medicine</topic><topic>Piperazines - administration & dosage</topic><topic>Piperidines - administration & dosage</topic><topic>Preventive medicine</topic><topic>Quality of Life</topic><topic>Rehabilitation Medicine</topic><topic>Side effects</topic><topic>Surveys and Questionnaires</topic><topic>Vomiting</topic><topic>Vomiting - chemically induced</topic><topic>Vomiting - prevention & control</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Gridelli, Cesare</creatorcontrib><creatorcontrib>Haiderali, Amin M.</creatorcontrib><creatorcontrib>Russo, Mark W.</creatorcontrib><creatorcontrib>Blackburn, Linda M.</creatorcontrib><creatorcontrib>Lykopoulos, Konstantinos</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Social Sciences Premium Collection</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Social Science Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>Social Science Premium Collection</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Sociology Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Social Science Database</collection><collection>Sociology Database</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><jtitle>Supportive care in cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Gridelli, Cesare</au><au>Haiderali, Amin M.</au><au>Russo, Mark W.</au><au>Blackburn, Linda M.</au><au>Lykopoulos, Konstantinos</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Casopitant improves the quality of life in patients receiving highly emetogenic chemotherapy</atitle><jtitle>Supportive care in cancer</jtitle><stitle>Support Care Cancer</stitle><addtitle>Support Care Cancer</addtitle><date>2010-11-01</date><risdate>2010</risdate><volume>18</volume><issue>11</issue><spage>1437</spage><epage>1444</epage><pages>1437-1444</pages><issn>0941-4355</issn><eissn>1433-7339</eissn><abstract>Purpose
The control of chemotherapy-induced nausea and vomiting (CINV) is critical in preventing poor health outcomes and increasing patient quality of life. The objective of this study was to evaluate the impact of the addition of casopitant to dual-combination therapy of dexamethasone and ondansetron on quality of life in patients receiving highly emetogenic chemotherapy (HEC).
Methods
In a multicenter, double-blind, randomized, placebo-controlled, add-on trial (
N
= 810), patients were randomized to intravenous (IV) ondansetron/dexamethasone alone (control) or in combination with either a single 150-mg oral dose of casopitant or 3-day IV/oral casopitant. Quality of life was assessed as impact of nausea and vomiting on daily life using the Functional Living Index Emesis (FLIE) questionnaire. Patients completed the FLIE questionnaire at baseline prior to receiving chemotherapy and after completion of the first cycle of HEC.
Results
Patients in the single oral dose and 3-day IV/oral casopitant groups scored higher mean total FLIE scores (115.7 and 114.0, respectively;
p
≤ 0.0332) than patients in the control group (107.5), indicating that casopitant patients experienced less impact from nausea and vomiting on daily life. The overall absolute difference in the proportion of patients reporting CINV with no impact on daily life between the single oral casopitant group and the control group was 13%; the difference between the 3-day IV/oral casopitant group and the control group was 14%.
Conclusion
The addition of casopitant to ondansetron and dexamethasone in patients receiving HEC was significantly more effective in reducing the impact of nausea and vomiting on all daily life activities as assessed by the FLIE compared with ondansetron/dexamethasone dual therapy.</abstract><cop>Berlin/Heidelberg</cop><pub>Springer-Verlag</pub><pmid>19882176</pmid><doi>10.1007/s00520-009-0766-4</doi><tpages>8</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0941-4355 |
| ispartof | Supportive care in cancer, 2010-11, Vol.18 (11), p.1437-1444 |
| issn | 0941-4355 1433-7339 |
| language | eng |
| recordid | cdi_proquest_journals_860959193 |
| source | MEDLINE; SpringerLink Journals |
| subjects | Activities of Daily Living Administration, Oral Adult Aged Aged, 80 and over Antiemetics - administration & dosage Antineoplastic Agents - adverse effects Antineoplastic Agents - therapeutic use Cancer Care and treatment Chemotherapy Clinical trials Dexamethasone Dexamethasone - therapeutic use Double-Blind Method Drug Therapy, Combination Female Health aspects Humans Male Medicine Medicine & Public Health Middle Aged Nausea Nausea - chemically induced Nausea - prevention & control Neoplasms - drug therapy Nursing Nursing Research Oncology Ondansetron - therapeutic use Original Article Pain Medicine Piperazines - administration & dosage Piperidines - administration & dosage Preventive medicine Quality of Life Rehabilitation Medicine Side effects Surveys and Questionnaires Vomiting Vomiting - chemically induced Vomiting - prevention & control Young Adult |
| title | Casopitant improves the quality of life in patients receiving highly emetogenic chemotherapy |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-04T02%3A33%3A54IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Casopitant%20improves%20the%20quality%20of%20life%20in%20patients%20receiving%20highly%20emetogenic%20chemotherapy&rft.jtitle=Supportive%20care%20in%20cancer&rft.au=Gridelli,%20Cesare&rft.date=2010-11-01&rft.volume=18&rft.issue=11&rft.spage=1437&rft.epage=1444&rft.pages=1437-1444&rft.issn=0941-4355&rft.eissn=1433-7339&rft_id=info:doi/10.1007/s00520-009-0766-4&rft_dat=%3Cgale_proqu%3EA358058266%3C/gale_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=860959193&rft_id=info:pmid/19882176&rft_galeid=A358058266&rfr_iscdi=true |